Additionally, Neo-CheckRay (NCT03875573) is an active phase II trial examining neoadjuvant chemotherapy and radiotherapy with the addition of durvalumab or oleclumab (anti-CD73 antibody) in luminal B breast cancer. The gene discussed is NT5E; the disease is breast carcinoma.